[go: up one dir, main page]

AR091457A1 - Tratamiento de celulas pluripotentes - Google Patents

Tratamiento de celulas pluripotentes

Info

Publication number
AR091457A1
AR091457A1 ARP130102110A AR091457A1 AR 091457 A1 AR091457 A1 AR 091457A1 AR P130102110 A ARP130102110 A AR P130102110A AR 091457 A1 AR091457 A1 AR 091457A1
Authority
AR
Argentina
Prior art keywords
pluripotent cells
gsk
inhibitor
tra1
ssea
Prior art date
Application number
Other languages
English (en)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR091457A1 publication Critical patent/AR091457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Reivindicación 1: Un método para expandir y diferenciar células pluripotentes; el método comprende las etapas de: a) cultivar células pluripotentes y b) tratar las células pluripotentes con un inhibidor de la actividad enzimática de GSK-3B. Reivindicación 4: El método de conformidad con la reivindicación 3, en donde las células que expresan marcadores de pluripotencia expresan por lo menos uno de los siguientes marcadores de pluripotencia seleccionados del grupo que consiste en: ABCG2, cripto, FoxD3, Connexin43, Connexin45, Oct4, SOX-2, Nanog, hTERT, UTF-1, ZFP42, SSEA-3, SSEA-4, Tra1-60 y Tra1-81. Reivindicación 7: El método de conformidad con la reivindicación 1, en donde las células pluripotentes se tratan con el inhibidor de la actividad enzimática de GSK-3B por aproximadamente 12 a aproximadamente 48 horas. Reivindicación 12: El método de conformidad con la reivindicación 1, en donde el inhibidor de la actividad enzimática de GSK-3B es un compuesto de la fórmula (1).
ARP130102110 2012-06-14 2013-06-14 Tratamiento de celulas pluripotentes AR091457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261741776P 2012-06-14 2012-06-14

Publications (1)

Publication Number Publication Date
AR091457A1 true AR091457A1 (es) 2015-02-04

Family

ID=49756254

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102110 AR091457A1 (es) 2012-06-14 2013-06-14 Tratamiento de celulas pluripotentes

Country Status (14)

Country Link
US (1) US20130337564A1 (es)
EP (1) EP2861723A4 (es)
JP (1) JP2015519085A (es)
KR (1) KR20150030709A (es)
CN (1) CN104603262A (es)
AR (1) AR091457A1 (es)
BR (1) BR112014031424A2 (es)
CA (1) CA2876671A1 (es)
MX (1) MX2014015419A (es)
PH (1) PH12014502748A1 (es)
RU (1) RU2015100900A (es)
SG (1) SG11201408150UA (es)
WO (1) WO2013192005A2 (es)
ZA (1) ZA201500224B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015021985B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos ou sais farmaceuticamente aceitáveis dos mesmos, respectivos usos e composição
KR102232650B1 (ko) 2013-06-11 2021-03-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
ES2985135T3 (es) 2014-12-18 2024-11-04 Harvard College Procedimientos para generar células ß derivadas de células madre y usos de las mismas
WO2016100930A1 (en) 2014-12-18 2016-06-23 President And Fellows Of Harvard College Methods for generating stem cell-derived b cells and methods of use thereof
US10443042B2 (en) 2014-12-18 2019-10-15 President And Fellows Of Harvard College Serum-free in vitro directed differentiation protocol for generating stem cell-derived beta cells and uses thereof
AU2017325511B2 (en) * 2016-08-18 2021-12-09 National University Of Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
CN115645621B (zh) 2016-11-10 2024-08-13 韦尔赛特公司 含有pdx1胰腺内胚层细胞的细胞递送装置及其方法
BR112019009746A2 (pt) 2016-11-16 2019-09-03 Cynata Therapeutics Ltd ensaio de células-tronco pluripotentes
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
JP2020518673A (ja) 2017-05-05 2020-06-25 フュージョン・ファーマシューティカルズ・インコーポレイテッド 二官能性キレートの薬物動態増強及びその使用
BR112019023249A8 (pt) 2017-05-05 2021-02-23 Centre For Probe Dev And Commercialization anticorpos monoclonais igf-1r e usos dos mesmos
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
KR101966523B1 (ko) * 2017-05-29 2019-04-05 차의과학대학교 산학협력단 오가노이드 배양을 위한 조성물 및 방법
US10391156B2 (en) 2017-07-12 2019-08-27 Viacyte, Inc. University donor cells and related methods
CA3082136A1 (en) 2017-11-08 2019-05-16 Avexis, Inc. Means and method for preparing viral vectors and uses of same
MX2020004939A (es) 2017-11-15 2020-11-11 Semma Therapeutics Inc Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.
KR20210018919A (ko) * 2018-06-08 2021-02-18 노파르티스 아게 약물 산물 효능을 측정하기 위한 세포-기반 분석
EP3833365A4 (en) 2018-08-10 2022-05-11 Vertex Pharmaceuticals Incorporated Stem cell derived islet differentiation
US20200080107A1 (en) 2018-09-07 2020-03-12 Crispr Therapeutics Ag Universal donor cells
US11118195B2 (en) 2019-09-05 2021-09-14 Crispr Therapeutics Ag Universal donor cells
AU2020340622A1 (en) 2019-09-05 2022-03-03 Crispr Therapeutics Ag Universal donor cells
JP2024503290A (ja) 2020-12-31 2024-01-25 クリスパー セラピューティクス アクチェンゲゼルシャフト ユニバーサルドナー細胞
WO2024124463A1 (zh) * 2022-12-15 2024-06-20 武汉睿健医药科技有限公司 一种吡咯并吡啶衍生物及其药物组合物与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060030042A1 (en) * 2003-12-19 2006-02-09 Ali Brivanlou Maintenance of embryonic stem cells by the GSK-3 inhibitor 6-bromoindirubin-3'-oxime
GB2444686B (en) * 2005-09-12 2010-08-25 Es Cell Int Pte Ltd Differentiation of pluripotent stem cells using p38 MAPK inhibitors or prostaglandins
US8741643B2 (en) * 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US8623648B2 (en) * 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US7939322B2 (en) * 2008-04-24 2011-05-10 Centocor Ortho Biotech Inc. Cells expressing pluripotency markers and expressing markers characteristic of the definitive endoderm

Also Published As

Publication number Publication date
EP2861723A2 (en) 2015-04-22
BR112014031424A2 (pt) 2017-06-27
SG11201408150UA (en) 2015-01-29
RU2015100900A (ru) 2016-08-10
JP2015519085A (ja) 2015-07-09
PH12014502748A1 (en) 2015-02-02
CA2876671A1 (en) 2013-12-27
WO2013192005A3 (en) 2014-03-13
KR20150030709A (ko) 2015-03-20
MX2014015419A (es) 2015-07-14
WO2013192005A2 (en) 2013-12-27
ZA201500224B (en) 2017-09-27
US20130337564A1 (en) 2013-12-19
EP2861723A4 (en) 2016-01-20
CN104603262A (zh) 2015-05-06

Similar Documents

Publication Publication Date Title
AR091457A1 (es) Tratamiento de celulas pluripotentes
AU2018260810A1 (en) Defined media for expansion and maintenance of pluripotent stem cells
RU2010147817A (ru) Плюрипотентные клетки
PH12014502686A1 (en) Differentiation of human embryonic stem cells into pancreatic endoderm
MX2021005715A (es) Derivacion sin alimentadores de celulas madre pluripotentes inducidas humanas con arn mensajero sintetico.
PH12015501450A1 (en) Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
MX2014012650A (es) Inhibidores de la expresión o función de smad7 para usarse en el tratamiento de diabetes y/o la promoción de la supervivencia de islotes pancreáticos después del trasplante.
NZ706806A (en) Compositions and methods for autologous germline mitochondrial energy transfer
SG195299A1 (en) Expansion of stem cells in hollow fiber bioreactors
WO2016168890A8 (en) Generation of muscle-lineage cells from stem cells
NZ627835A (en) Feeder-free method for culture of bovine and porcine spermatogonial stem cells
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
PH12014501426A1 (en) Induced pluripotent stem cells from human umbilical cord tissue-derived cells
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
IL275568A (en) Efficient production of stable multipotent prime embryonic stem cells
AU2012256014A8 (en) Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
MX2019005476A (es) Ensayo de celulas madre pluripotentes.
PH12018502061A1 (en) Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
MX2016014008A (es) Metodo para diferenciacion de celulas madre pluripotentes en cardiomiocitos.
PL3436568T3 (pl) Podłoże hodowlane do pluripotencjalnych komórek macierzystych
BR112015015466A2 (pt) método para cultivar células-tronco pluripotentes
BR112016030510A2 (pt) proteína do complexo de hemaglutinina mutante, e método para cultivo de células-tronco pluripotentes usando a mesma
RU2014129842A (ru) Индуцированные плюрипотентные стволовые клетки, полученные из клеток, выделенных из почек человека
CY1123057T1 (el) Μεθοδος για παραγωγη επαγομενου πολυδυναμου βλαστοκυτταρου απο μεσεγχυματικο βλαστοκυτταρο και επαγομενου πολυδυναμου βλαστοκυτταρου που παραγεται με τη μεθοδο
MY188869A (en) Process and compositions for achieving mammalian energy balance

Legal Events

Date Code Title Description
FB Suspension of granting procedure